Sonogen Medical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Sonogen Medical is a private, pre-revenue medical device startup targeting the significant problem of delayed and non-union bone fractures. The company's core innovation is a next-generation bone growth stimulation (BGS) device that applies a patent-pending acoustic shear wave signal, designed to be more effective, convenient (20 minutes daily use), and data-connected than existing antiquated technologies. Backed by a seasoned team and advisors, Sonogen aims to improve patient outcomes and democratize access to advanced orthopedic care through its portable therapeutic and diagnostic ultrasound platform.

OrthopedicsMusculoskeletal

Technology Platform

Proprietary acoustic shear wave ultrasound signal for bone stimulation combined with Agentic Fracture Assessment (AFA) software for automated healing monitoring via ultrasound data.

Opportunities

The large and underserved market of over 600,000 annual non-union fractures in the US alone presents a major opportunity.

Sonogen's modern, convenient, and data-connected solution could capture significant share from outdated bone growth stimulators and potentially expand into broader fracture healing acceleration.

Risk Factors

Key risks include failure to demonstrate clinical efficacy in human trials, challenges in obtaining FDA regulatory clearance, securing reimbursement from payors, and competing against established medical device companies with greater resources and commercial infrastructure.

Competitive Landscape

Sonogen competes in the bone growth stimulation (BGS) market against established players like Bioventus (Exogen), Orthofix, and Zimmer Biomet, which use older electromagnetic or ultrasound technologies. Its primary competitive edge is its modern, patient-friendly design (20 min/day, portable, connected) and proprietary acoustic signal, but it must overcome the incumbents' strong surgeon relationships and payer contracts.

More companies in Regenerative Medicine →More companies in United States →